Scarica l'app Stockscreener
137.19
0.86%
1.315
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$135.87
Aprire:
$136.94
Volume 24 ore:
200.39K
Relative Volume:
0.03
Capitalizzazione di mercato:
$170.52B
Reddito:
$29.79B
Utile/perdita netta:
$9.22B
Rapporto P/E:
18.67
EPS:
7.3494
Flusso di cassa netto:
$10.23B
1 W Prestazione:
+4.72%
1M Prestazione:
+4.29%
6M Prestazione:
-11.58%
1 anno Prestazione:
+14.07%
Intervallo 1D:
$136.36
$137.91
Intervallo di 1 settimana:
$130.59
$137.19
Portata 52W:
$108.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Nome
Gilead Sciences Inc
Settore
Industria
Telefono
(650) 574-3000
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
137.53 | 168.47B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,225.35 | 1.09T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
261.26 | 628.65B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
252.90 | 439.59B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
134.16 | 327.94B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
152.72 | 289.52B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Iniziato | Jefferies | Buy |
| 2026-02-20 | Iniziato | Barclays | Equal Weight |
| 2026-02-11 | Reiterato | Needham | Buy |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-08-19 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Aggiornamento | Truist | Hold → Buy |
| 2025-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Reiterato | Oppenheimer | Outperform |
| 2025-02-18 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Aggiornamento | DZ Bank | Hold → Buy |
| 2025-01-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2024-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Reiterato | Maxim Group | Buy |
| 2024-04-24 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Downgrade | Truist | Buy → Hold |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-09-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-09-06 | Iniziato | HSBC Securities | Reduce |
| 2023-07-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-16 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Ripresa | Piper Sandler | Overweight |
| 2023-01-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Ripresa | BofA Securities | Neutral |
| 2022-12-09 | Downgrade | DZ Bank | Buy → Hold |
| 2022-10-31 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Reiterato | BMO Capital Markets | Market Perform |
| 2022-10-28 | Reiterato | Cowen | Outperform |
| 2022-10-28 | Reiterato | JP Morgan | Overweight |
| 2022-10-28 | Reiterato | Jefferies | Buy |
| 2022-10-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-10-28 | Aggiornamento | Truist | Hold → Buy |
| 2022-10-28 | Reiterato | Wells Fargo | Equal Weight |
| 2022-10-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-28 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-02 | Reiterato | BofA Securities | Neutral |
| 2022-02-02 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-02-02 | Reiterato | Truist | Hold |
| 2022-02-02 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Argus | Hold → Buy |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Ripresa | Piper Sandler | Neutral |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-07-30 | Reiterato | BMO Capital Markets | Market Perform |
| 2021-07-30 | Reiterato | RBC Capital Mkts | Outperform |
| 2021-04-01 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-09-30 | Ripresa | Jefferies | Buy |
| 2020-09-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-31 | Reiterato | Credit Suisse | Neutral |
| 2020-07-31 | Reiterato | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Reiterato | Piper Sandler | Overweight |
| 2020-07-31 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-07-31 | Reiterato | SunTrust | Hold |
| 2020-07-31 | Reiterato | Wells Fargo | Equal Weight |
| 2020-07-20 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Aggiornamento | SunTrust | Sell → Hold |
| 2020-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Downgrade | SunTrust | Hold → Sell |
| 2020-04-27 | Downgrade | UBS | Buy → Neutral |
| 2020-04-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Downgrade | CFRA | Hold → Sell |
Mostra tutto
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Thomasville National Bank Purchases New Shares in Gilead Sciences, Inc. $GILD - MarketBeat
Moody Lynn Lieberson & Walker LLC Has $13.33 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Why Gilead Sciences (GILD) Is Back In The Spotlight - Yahoo Finance UK
5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call - Yahoo! Finance Canada
Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics - Yahoo Finance
FY2026 EPS Estimates for Gilead Sciences Reduced by Analyst - MarketBeat
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today - Benzinga
MacroGenics stock rises on $10M Gilead option exercise By Investing.com - Investing.com South Africa
MacroGenics stock rises on $10M Gilead option exercise - Investing.com
Gilead Sciences (GILD) EVP converts 6,002 RSUs, with 2,908 shares withheld - Stock Titan
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program - The Manila Times
Gilead Sciences options activity points to institutional conviction on 2026 upside - Investing.com
Gilead Sciences Target of Unusually High Options Trading (NASDAQ:GILD) - MarketBeat
FY2027 EPS Estimate for Gilead Sciences Lowered by Analyst - MarketBeat
Handelsbanken Fonder AB Has $123.19 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
E. Ohman J or Asset Management AB Has $5.66 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Why Gilead Sciences (NASDAQ:GILD) Just Won a Key Drug Development Case? - Kalkine Media
Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade) - Seeking Alpha
Gilead Sciences, Inc. (GILD) Stock Analysis: Exploring a Potential 18.16% Upside with Robust Pipeline and Strategic Collaborations - directorstalkinterviews.com
Gilead Sciences, Inc. Revenue Breakdown – SIX:GILD - TradingView
Ebola response turns to Merck vaccine, Gilead drug as Congo outbreak worsens - The Spokesman-Review
AB RELATIVE VALUE FUND, INC.'s Gilead Sciences Inc(GILD) Holding History - GuruFocus
Should Gilead’s Swing to a Full‑Year Loss Outlook Require Action From Gilead Sciences (GILD) Investors? - webull.com
Key HIV stat over 70% leaves BofA siding with Gilead - thestreet.com
Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results - The National Law Review
Ebola Response Turns to Merck Vaccine, Gilead Drug as Congo Outbreak Worsens - Bloomberg.com
GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength - theglobeandmail.com
Czech National Bank Raises Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
PensionDanmark Pensionsforsikringsaktieselskab Purchases 25,515 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
NewEdge Advisors LLC Buys 231,715 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Assenagon Asset Management S.A. Boosts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ: GILD) sets up automatic shelf for wide range of securities - Stock Titan
GILEAD SCIENCES, INC. 2026: Revenue $7.8B, EPS ($8.45) — 10-Q Summary - TradingView
Gilead Sciences: A Strong Quarter Hidden Behind A Bottom-Line Loss (NASDAQ:GILD) - Seeking Alpha
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Gilead Sciences Delivers 'Plenty' to Like in Q2, RBC Says - Moomoo
Gilead Sciences (NASDAQ:GILD) Given New $123.00 Price Target at Royal Bank Of Canada - MarketBeat
Gilead Sciences Inc Stock (GILD) Moved Down by 3.96% on Aug 5: A Full Analysis - TradingKey
Gilead (GILD) Faces HIV Drug Access Criticism From AIDS Healthcare Foundation - finance.yahoo.com
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch - BioPharma Dive
Leerink Partners Adjusts Price Target on Gilead Sciences to $130 From $126 - Moomoo
Goldman Sachs Adjusts Price Target on Gilead Sciences to $135 From $130 - Yahoo Finance
Gilead Sciences, Inc. Declares Quarterly Dividend of $0.82 (NASDAQ:GILD) - MarketBeat
The Bull Case For Gilead Sciences (GILD) Could Change Following Deeper 2026 Losses Amid HIV, Oncology Growth - Yahoo Finance
Gilead's Steady Long-Term Growth Prospects in HIV and Expansion in Oncology Support a Wide Moat - Morningstar
Gilead Sciences Inc (GILD) (Q2 2026) Earnings Call Highlights: PrEP Sales Double to $1B, HIV ... - Yahoo Finance
Gilead Sciences Inc (GILD) (Q2 2026) Earnings Call Highlights: P - GuruFocus
Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Stock - MarketBeat
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results - Business Wire
Gilead Sciences Inc Azioni (GILD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.65%
0.99%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):